Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University
26 mars 2024 07h30 HE
|
Optimi Health Corp.
Supply agreement marks Optimi’s first international shipment of research-grade active pharmaceutical ingredient (API) MDMA to Israel
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
20 mars 2024 10h20 HE
|
PharmAla Biotech
PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
18 mars 2024 08h55 HE
|
PharmAla Biotech
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme
MAPS Provides Psychedelic Crisis Assessment and Intervention Training to Denver’s First Responders
11 mars 2024 11h50 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS uses its over 30 years of experience in the psychedelic space to offer a first-of-its-kind gold-standard training program.
PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
08 mars 2024 16h15 HE
|
PharmAla Biotech
PharmAla provides corporate update following AGM
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
04 mars 2024 08h00 HE
|
atai Life Sciences
The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation of DMTVLS-01 is being developed...
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
28 févr. 2024 17h00 HE
|
atai Life Sciences
NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
Optimi Announces Closing of First Tranche of Non-Brokered Private Placement
28 févr. 2024 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and...
PharmAla named an Intellectual Property Ontario Client
22 févr. 2024 08h55 HE
|
PharmAla Biotech
PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.
PharmAla Data to be Published in ACS Chemical Neuroscience
20 févr. 2024 08h55 HE
|
PharmAla Biotech
PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans